Endelig sker der lidt, udover konferencer. Godt nok først opstart i 2022, men bedre end ingenting:
https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2021/Hansa-Biopharma-to-initiate-Phase-3-study-of-imlifidase-to-treat-anti-Glomerular-Basement-Membrane-anti-GBM-disease-after-successful-pre-IND-meeting-with-U.S.-FDA/default.aspx
https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2021/Hansa-Biopharma-to-initiate-Phase-3-study-of-imlifidase-to-treat-anti-Glomerular-Basement-Membrane-anti-GBM-disease-after-successful-pre-IND-meeting-with-U.S.-FDA/default.aspx
Jeg synes, det er fantastiske resultater, de viser!!
Du er ikke den eneste 
Hansa Biopharma; FDA opens the door for the next pivotal Phase 3 study
https://www.redeye.se/research/826272/hansa-biopharma-fda-opens-the-door-for-the-next-pivotal-phase-3-study
Uddrag: "In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement."
"....... Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600)."
Hansa Biopharma; FDA opens the door for the next pivotal Phase 3 study
https://www.redeye.se/research/826272/hansa-biopharma-fda-opens-the-door-for-the-next-pivotal-phase-3-study
Uddrag: "In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement."
"....... Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600)."
